ArticleThe New England journal of medicine2020
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply.
Article in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Trial
- Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.Journal of experimental & clinical cancer research : CR · 2023Trial
- NCancer reports (Hoboken, N.J.) · 2026Article
- Programmable local immunochemotherapy for triple-negative breast cancer via spatiotemporally controlled release of CpG oligodeoxynucleotides, gemcitabine, and paclitaxel.NPJ breast cancer · 2026Article
- Real-World Epidemiology, Clinical Characteristics and Outcomes of Women with Germline BRCA Mutation and Early Breast Cancer in China.Oncology and therapy · 2025Article
- Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis.Breast cancer research and treatment · 2025Article
- Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germlineThe Lancet regional health. Western Pacific · 2025Article
- Immunotherapy boosts responses in hormone receptor-positive breast cancers.Nature medicine · 2025Article
- Targeting CD276 for T cell-based immunotherapy of breast cancer.Journal of translational medicine · 2024Article
- Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer.NPJ breast cancer · 2024Article
- Interrogating the roles of lymph node metastasis in systemic immune surveillance.Clinical & experimental metastasis · 2024Review
- Function and mechanism of action of the TRPV1 channel in the development of triple-negative breast cancer.Acta biochimica et biophysica Sinica · 2024Review
- Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow.Journal for immunotherapy of cancer · 2024Article
- MDR1-EXPRESSING CD4Journal for immunotherapy of cancer · 2023Article
- Intratumoral CD103Cancer communications (London, England) · 2023Article
- T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy.Journal for immunotherapy of cancer · 2023Article
- Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records.Journal for immunotherapy of cancer · 2023Article
- Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.World journal of surgical oncology · 2023Article
- Article
- Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer.Cancers · 2022Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32579835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.